DUBLIN–(BUSINESS WIRE)–The “Oral Solid Dosage Manufacturing Market Industry Trends and Global Forecasts to 2035, by Type of Finished Dosage Form, Type of Packaging, Scale of Operation, Company Size, Therapeutic Area, and Key Geographical Regions” report has been added to ResearchAndMarkets.com’s offering.
The global oral solid dosage manufacturing market is estimated to grow from USD 22.5 billion in 2024 to reach USD 23.7 billion in 2025 and USD 36.5 billion by 2035, representing a higher CAGR of 4.4% during the forecast period.
Oral Solid Dosage Contract Manufacturing Market: Growth and Trends
Despite several novel dosage forms being introduced into the pharmaceutical and nutraceutical sectors, oral solid drugs (OSD), particularly tablets and capsules, continue to be the most popular and widely used delivery forms. This is due to the fact that these formulations offer various advantages, including self-administration, stability, cost-effectiveness, convenience of handling, transportation and patient compliance. This mature yet high-value vertical of the overall pharmaceutical industry represents about 90% of the global market share of all formulations intended for human use.
However, OSD manufacturing operations is a complex process requiring specialized equipment and facilities, highly contained working environments and experts with multidisciplinary knowledge. Further, recent evolution to address the upstream bottlenecks associated with active pharmaceutical ingredients (API), such as poor bioavailability, low solubility, bitter taste and high potency, necessitate extensive technical expertise. As a result, drug developers are increasingly relying on contract service providers to leverage their capabilities and yield cost savings opportunities.
Unlike drug developers, the capabilities of these third-party service providers are usually more focused on their respective service portfolios. They support pharmaceutical companies with specialized capabilities ranging from process and formulation development to drug substance characterization, analytical method development, and regulatory filings, as well as capacity for clinical and commercial manufacturing. Considering the growing trend of outsourcing and the ongoing efforts of service providers to improve / expand their offerings, it is anticipated that the oral solid dosage contract manufacturing market is likely to evolve at a steady pace, in the mid to long term.
Oral Solid Dosage Contract Manufacturing Market: Key Insights
The report delves into the current state of the oral solid dosage contract manufacturing market and identifies potential growth opportunities within the industry.
Some key findings from the report include:
- Presently, over 300 companies claim to have the required expertise to offer contract manufacturing services for a broad spectrum of oral solid dosage forms, including modified release formulations of tablets and capsules.
- Nearly 30% of the players have established end-to-end capabilities, from early development to packaging of oral solids in a variety of containers; this simplifies supplier management activities for sponsor companies.
- The current market landscape features the presence of both established and emerging players engaged in the manufacturing of oral solid dosages at various scales of operation, in compliance with the regulatory standards.
- With more than 1,350 facilities, oral solid contract manufacturers have established global presence; majority of these players are based in the Asia-Pacific region, primarily in countries, such as China and India.
- As part of their growth strategy, CMOs are investing in either expanding their existing facilities / capabilities or building facilities in other regions; majority of these initiatives were undertaken in North America.
- The global installed oral solid dosage contract manufacturing capacity is spread across various geographies; over 30% of this capacity is dedicated to the manufacturing of tablets on a commercial scale.
- The demand for oral solid dosage contract manufacturing is rising significantly owing to the growing complexity of APIs; by 2035, it is anticipated to reach over 35,000 metric tonnes, across clinical and commercial scales.
- Driven by volume shifts from originators to generics and over-investments to create safety buffers, the contract manufacturing domain is currently witnessing an excess in capacity, thereby propelling consolidation efforts.
- Over 65% of the market is expected to be captured by revenues from manufacturing anti-cancer drugs, including those based on HPAPIs; furthermore, North America based players are likely to contribute majorly to this domain.
Oral Solid Dosage Contract Manufacturing Market: Research Coverage
- Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the oral solid dosage contract manufacturing market, focusing on key market segments, including type of finished dosage form, type of packaging, scale of operation, company size, therapeutic area and key geographical regions.
- Market Landscape: A comprehensive evaluation of companies offering contract services for oral solid dosage form, considering various parameters, such as year of establishment, company size (in terms of the number of employees), location of headquarters, company ownership, type of service(s) offered, type of finished dosage form(s) manufactured, type of packaging offered, scale(s) of operation and additional manufacturing capabilities.
- Company Competitiveness Analysis: A comprehensive competitive analysis of oral solid dosage contract manufacturing service providers, examining factors, such as supplier strength and service strength.
- Regional Capability Analysis: A comprehensive regional capability assessment framework the oral solid dosage contract manufacturers that evaluates key geographies by various parameters, including type of service(s) offered, type of finished dosage form(s) manufactured, type of packaging offered, scale(s) of operation and location of manufacturing facilities of the service providers.
- Company Profiles: In-depth profiles of key oral solid dosage contract manufacturers, focusing on company overviews, financial information (if available), oral solid dosage service portfolio, manufacturing capabilities and facilities, recent developments and an informed future outlook.
- Make Versus Buy Decision Framework: An insightful framework that emphasizes the key indicators and factors that need to be considered by oral solid dosage drug developers to determine whether to manufacture their respective products in-house or outsource the manufacturing operation to contract service providers.
- Recent Expansions: An examination of the different expansion efforts made by service providers in this field to enhance their manufacturing capabilities. This analysis considers various factors, including the year of expansion, purpose of expansion, type of an estimate of the global installed capacity (in terms of number of oral solid units and volume of API) for the manufacturing of oral solids, based on information provided by various industry stakeholders in the public domain. It also features the distribution of the available capacity on the basis of company size, scale of operation, type of finished dosage form and key geographical regions. Overall, the analysis represents a holistic view of the supply-side of the market, allowing us to present an informed opinion on whether the present capacity will be able to meet the likely future demand.
- Demand Analysis: Informed estimates of the annual commercial and clinical demand for oral solid doses based on several relevant parameters, such as key geographical regions and therapeutic areas.
- Total Cost of Ownership: A detailed analysis of the total cost of ownership for an oral solid dosage contract manufacturing service provider, highlighting the expenses associated with the establishment and maintenance of an oral solid dosage manufacturing facility, over a period of 20 years.
- Regulatory Landscape: A discussion on general regulatory guidelines laid down by major regulatory bodies, across different countries, featuring an elaborative assessment of several CMOs engaged in this domain, along with information on their operational approvals, certifications received, and relative popularity of the key regulatory body. Additionally, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies.
- Case Study 1: A general discussion on taste masking service providers for oral solids, providing information on scale of operation, manufacturing scalability, other service(s) offered along with information on type of formulation, end users, techniques used for taste masking, branch of healthcare and regional capability. Further, the chapter includes the current market landscape of taste masking technology providers, providing information on technology name, techniques used, type of finished dosage form, end users along with information on patent, availability of technology for partnerships and licensing. In addition, the chapter provides details on the year of establishment, company size and location of headquarters.
- Case Study 2: A general discussion on drug bioavailability enhancement service providers for oral solids, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, bioavailability enhancement principle supported, bioavailability enhancement approach employed, including solid dispersion, size reduction, lipid-based, and other bioavailability enhancement approaches, type of dosage form supported (solids, fine particles and semi-solids).
Key Players in the Oral Solid Dosage Contract Manufacturing Market, Profiled in the Report Include:
- Aenova
- Alcami
- Almac
- Cambrex
- Hetero Drugs
- Ind-Swift Laboratories
- Lonza
- Rubicon Research
Key Questions Answered in this Report
- How many companies are currently engaged in this market?
- Which are the leading companies in this market?
- What factors are likely to influence the evolution of this market?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Reasons to Buy this Report
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
Additional Benefits
- Complimentary PPT Insights Packs
- Complimentary Excel Data Packs for all Analytical Modules in the Report
- 10% Free Content Customization
- Detailed Report Walkthrough Session with Research Team
For more information about this report visit https://www.researchandmarkets.com/r/h38o7b
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900